MODAFINIL (modafinil) by Aurobindo Pharma is mechanism(s) through which modafinil promotes wakefulness is unknown. Approved for excessive sleepiness, wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (osa) and 1 more indications. First approved in 2012.
Drug data last refreshed 21h ago
mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although the pharmacologic profile is not identical to that of the sympathomimetic amines. Modafinil-induced…
Worked on MODAFINIL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sympathomimetic-like Agent
A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)
Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)
The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo